Finally, the current results indicate that upregulation of CST1 is a risk factor for tumor recurrence and metastasis, and its expression associated with clinicopathological parameters may act as an independent predictor for patient survival and a therapeutic target in breast cancer patients. This evidence concerns the gene CST1 and neoplasm.